Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.49
-0.02 (-3.54%)
At close: Jul 24, 2025, 3:59 PM
Theriva Biologics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -24.81M | -25.65M | -26.69M | -22.27M | -19.04M | -18.35M | -18.45M | -20.01M | -19.89M | -19.68M | -19.36M | -17.78M | -16M | -14.27M | -11.14M | -9.97M | -9.66M |
Depreciation & Amortization | 124K | 137K | 149K | 148K | 142K | 135K | 121K | 113K | 99K | 85K | 73K | 67K | 72K | 87K | 106K | 141K | 176K |
Stock-Based Compensation | 611K | 671K | 654K | 612K | 586K | 552K | 536K | 522K | 489K | 475K | 457K | 438K | 427K | 416K | 404K | 384K | 368K |
Other Working Capital | -311K | -123K | 1.82M | 3.43M | 3.39M | 2.47M | 756K | -1.07M | -386K | -421K | 1.79M | 1.87M | 1.13M | 1.24M | -848K | -1.34M | -943K |
Other Non-Cash Items | 7.6M | 8.11M | 6.69M | 1.65M | -1.71M | -2M | 1.81M | 3.51M | 2.49M | 2.41M | 746K | -28K | 656K | 952K | -43K | 647K | 456K |
Deferred Income Tax | 223K | n/a | -1.09M | -1.4M | -1.53M | -1.64M | -2.64M | -2.11M | -1.75M | -1.43M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 2K | n/a | 1.71M | 3.63M | 3.48M | 2.31M | 801K | -1.35M | -1.22M | -806K | 560K | 1.53M | 1.04M | 875K | -585K | -1.8M | -1.57M |
Operating Cash Flow | -16.81M | -16.94M | -18.79M | -17.83M | -18.27M | -19M | -17.82M | -19.33M | -19.79M | -19.08M | -18.52M | -16.22M | -14.46M | -12.89M | -11.21M | -11.11M | -10.54M |
Capital Expenditures | -1K | -1K | -57K | -186K | -194K | -202K | -237K | -119K | -124K | -116K | -25K | -14K | n/a | -14K | -19K | -23K | -23K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | 417K | 417.42K | 417.42K | -3.86M | -4.28M | -4.28M | -4.28M | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | -417K | -417K | -417K | -417K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | 417K | 417K | 417K | 417K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | -417K | -417.42K | -417.42K | -834.42K | -417.42K | -417K | -417K | n/a | n/a | n/a | n/a |
Investing Cash Flow | -1K | -1K | -57K | -186K | -194K | -202K | -237K | -119K | -124K | -4.4M | -4.3M | -4.29M | -4.28M | -14K | -19K | -23K | -23K |
Debt Repayment | n/a | n/a | n/a | n/a | -20K | -75K | -75K | -75K | -55K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | -288K | -288K | -288K | -288K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 12.34M | 9.21M | 3.97M | 254K | 637K | 637K | -844K | 1.89M | -266K | -1.64M | 1.36M | -1.38M | -1.38M | 8.04M | 11.4M | 11.4M | 11.4M |
Financial Cash Flow | 8.57M | 5.5M | 4.03M | 317K | 680K | 625K | -1.21M | 1.53M | -609K | -1.93M | 1.36M | -1.38M | -1.38M | 74M | 77.36M | 77.36M | 77.36M |
Net Cash Flow | -8.25M | -11.57M | -14.75M | -17.66M | -17.82M | -18.61M | -19.32M | -18.01M | -20.62M | -25.44M | -21.55M | -21.93M | -20.09M | 61.1M | 66.13M | 66.23M | 66.8M |
Free Cash Flow | -16.81M | -16.94M | -18.84M | -18.01M | -18.46M | -19.2M | -18.06M | -19.45M | -19.91M | -19.2M | -18.55M | -16.24M | -14.46M | -12.9M | -11.23M | -11.13M | -10.56M |